This study explored the potential benefits of combining first-generation epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor with chemotherapy as a neoadjuvant treatment for patients with stage III N2 EGFR-mutant non-small cell lung cancer. This evidence concerns the gene EGFR and non-small cell lung carcinoma.